| Revenue Growth | Greenbrook up 17% to $26.9M; Neurostar capital up double-digits; sessions down double-digits. |
|---|---|
| Mgmt Confidence | High confidence in new commercial models and Greenbrook operational discipline improvements. |
| Demand Visibility | Utilization up 10% in active accounts; 40% unused capacity at Greenbrook. |
| Margin Trends | Gross margin 51.1% vs 46.6% LY; FY2026 guidance raised to 48%-50%. |
| Op. Leverage | Clinics carry fixed costs; increasing occupancy from 60% drives significant profitability. |
| Pricing Power | Improved reimbursement rates through effective payer contracting for TMS and Spravado. |
| Vol vs Price | Growth driven by Greenbrook volume and improved revenue cycle management pricing. |
| Segment Growth | Greenbrook clinics outperforming; Neurostar transitioning from recurring sessions to capital sales. |
| New Clients | Expanded Neurostar pilot to broader rollout; collaboration with A&T Neuro announced. |
| Capex & Debt | Raised $7.6M via ATM; cash balance $25M; reduced cash burn significantly. |
| Regulatory | Monitoring Compass Pathways' psilocybin regulatory path for future Greenbrook delivery integration. |
| Commentary | Shifting from high-touch session model to flexible capital and a-la-carte support. |
| New Launches | Introduced Neurostar lease-finance options and a-la-carte clinical support services. |
Growth
Total revenue $41.6M (up 9%); Greenbrook revenue $26.9M (up 17%); Neurostar revenue $14.7M (down 2.7%).
Outlook
Narrowed FY2026 revenue guidance to $160M-$164M; targeting positive cash flow in second half 2026.
Risks
Neurostar session revenue fell double-digits; management pivoted to holistic reporting, potentially obscuring specific segment declines.
The company's earnings call, NASDAQ: STIM, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Neuronetics, Inc.: key numbers
- Share price
- $1.25Close, Nov 16
- Market cap
- $97.2M
- Shares outstanding
- 77.73MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Neuronetics, Inc.
All →Neuronetics Insider Jorey Chernett Buys $79.6K of Stock
Jorey Chernett bought 40,000 shares of Neuronetics, Inc. at $1.99 a share, worth $79.6K in total on Nov 9, 2026. Shares held after the trade: 10,306,225 (+0.4%).
- Value
- $79.6K
- Shares
- 40,000
- Price
- $1.99
- Holding change
- +0.4%
- Trade date
- Nov 9, 2026
Neuronetics Insider Jorey Chernett Sells $4.48M of Stock
Jorey Chernett sold 3,335,411 shares of Neuronetics, Inc. at $1.15 to $2.39 a share (average $1.34) in 5 transactions, worth $4.48M in total between Nov 6, 2026 and Nov 13, 2026. Shares held after the trade: 7,325,577 (-23.0%).
- Value
- $4.48M
- Shares
- 3,335,411
- Average price
- $1.34
- Holding change
- -23.0%
- Trade date
- Nov 6, 2026 to Nov 13, 2026
Neuronetics Capital Raise of $30M
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.
- Value
- $30M
- Counterparty
- William Blair & Company, L.L.C.
Neuronetics Capital Raise of $30M
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at $1.60 per share, with an additional 2,812,500 shares available via an underwriters' option. The company expects to raise approximately $30 million in gross proceeds ($27.7 million net) to repay debt under its Perceptive Credit Facility and for general corporate purposes.
- Value
- $30M
- Counterparty
- William Blair & Company, L.L.C.
Neuronetics Debt Financing Update with Perceptive Credit Holdings IV, LP
Neuronetics entered into Amendment No. 6 to its existing Credit Agreement with Perceptive Credit Holdings IV, LP to modify certain revenue covenants. The amendment is subject to an optional prepayment of at least $15 million plus interest and fees, and will automatically terminate if conditions are not met by November 30, 2026.
- Counterparty
- Perceptive Credit Holdings IV, LP
Neuronetics Q3 2026 Results: Net Loss of $1.69M, Loss Narrows
Neuronetics, Inc. reported total revenues of $41.96 million for the quarter ended September 30, 2026, a 12.5% increase over the prior year, driven primarily by growth in the Greenbrook segment. The company achieved a quarterly income from operations of $0.54 million compared to a loss of $7.32 million in the prior year, though it maintained a net loss of $1.56 million for the period.
- Key figure
- Net loss $1.69M